SEC Form 4 · accession 0001415889-15-000245
INNOVUS PHARMACEUTICALS, INC. · INNV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lynnette Dillen
Officer — EVP, CFO
Period of report
Jan 21, 2015
Accepted (ET)
Jan 23, 2015 · 5:15 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001411879
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| WarrantsF3,F1,F2 | $0.30 | Jan 21, 2015 | P | 250,000 | A | Jan 21, 2015 | Jan 21, 2020 | Common Stock | 250,000 | 250,000 | D |
Explanation of responses
- F1The warrants contain anti-dilution protection, including ratchet protection upon dilutive issuances, provided that, if the Issuer closes a financing that results in net proceeds of at least $1 million to the Issuer on or prior to March 31, 2015 and the promissory notes issued in connection with the warrants are repaid in full within 10 days of receipt of such funds, the dilutive issuance anti-dilution protection is eliminated and the exercise price of the warrants is reset to $0.075 per share.
- F2The reporting person may not exercise the warrant if such exercise would result in the reporting person or any of its affiliates would beneficially own more than 9.99% of Common Stock.
- F3The warrants were issued in connection with a promissory note sold by the Issuer to the Reporting Person.